Santen Publishes its Annual Integrated Report “Santen Report 2024”
September 18, 2024, Osaka, Japan – Santen Pharmaceutical Co., Ltd. (hereinafter Santen) today announced the release of the “Santen Report 2024” (Integrated Report for the fiscal year ended March 31, 2024). Available in both English and Japanese, the report is a comprehensive source of financial and non-financial information. The report can be accessed on Santen’s investor relations (IR) website (https://www.santen.com/en/ir/document/annual).
Since its establishment in Japan in 1890, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. As a specialty company focusing on eye health that is committed to demonstrating the value of “People Centricity” in everything we do, we aspire to realize “Happiness with Vision” by providing valuable products and services to consumers, patients, and medical professionals around the world.
This edition of the report includes both financial and non-financial information related to our medium-term strategies and initiatives for growth, the management foundation for strategy implementation, and how Santen intends to create further value for patients and society. Santen will continue to dedicate itself to effective communication with stakeholders and the creation of corporate value in pursuit of "Happiness with Vision".
Overview of Santen Report 2024:
Introduction: Santen Values
- Learn about Santen’s CORE PRINCIPLE and commitment to realizing “Happiness with Vision” by providing valuable products and services to consumers, patients, and medical professionals around the world.
Value Creation Stories and Growth Strategies
- Takeshi Ito, President and CEO, Member of the Board, reviews the results from and progress made during the first year of the Medium-Term Management Plan (FY2023-FY2025) and explains how Santen will contribute to solving social issues related to eye health and to the sustainable development of society.
- Kazuo Koshiji, Chief Financial Officer, reviews the achievements of the Medium-Term Management Plan for FY2023 and explains the financial strategy that will support implementation of the plan.
- Rie Nakajima, Chief Operating Officer, Member of the Board, discusses Santen's strategy for accelerating global business growth through its emphasis on commercial excellence, with a view to achieving exponential growth.
- Kentaro Kakihana, Global Head of Human Resources, explains the human capital strategy for realizing Santen’s vision, including the recruitment model and employee engagement and development initiatives and challenges.
Initiatives for Sustainable Growth/Management Foundations Supporting Sustainable Growth
- Overview of Santen's Sustainability Commitment, which seeks to contribute to the sustainable development of society while enhancing corporate value over the medium to long term. In terms of Materiality, the most important are “market penetration of products with social significance” and “people development and promotion,” which will lead to realization of the new Medium-Term Management Plan and sustainable growth beyond it. Specifically, this section introduces how Santen is developing products in new fields such as myopia, advancing the market penetration of domestic and overseas products and their further value contribution to patients, using allergic conjunctivitis and glaucoma as examples, and realizing a work environment in which a diverse workforce can thrive.
- In addition, the report includes examples of activities to improve access to medical care, digital transformation (DX), and penetration of the CORE PRINCIPLE to support medium- to long-term business growth.
Corporate Governance
- Explanation of how credible and transparent activities and governance system support the sustainable development of Santen and society.
- Inaugural messages from the new chairs of the Board of Directors, Nominating Committee and Executive Compensation Committee and a dialogue between Outside Director and the Company's Corporate Officer on the role of the Board of Directors.
About Santen
As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of “Happiness with Vision” by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, “Tenki ni sanyo suru,” Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen’s mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience “Happiness with Vision.”
For more information, please visit Santen’s website https://www.santen.com/en.
Contact
Corporate Communications
Santen Pharmaceutical Co., Ltd.
E-mail: communication@santen.com
Official SNS
